CLINICAL TRIAL: ADENOVIRUS CD-154 IN SUBJECTS WITH CLL

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 主要目标 确定和监测非霍奇金淋巴瘤（NHL）患者的生物学反应，仅限于滤泡性淋巴瘤、弥漫性大细胞淋巴瘤、套细胞淋巴瘤和小淋巴细胞淋巴瘤/慢性淋巴细胞白血病（SLL/CLL）患者接受重复结内注射Ad-ISF 35治疗。 次要目的 第一章 确定Adenovirus-CD 154（Ad-ISF 35）直接注射至非霍奇金淋巴瘤（NHL）患者淋巴结重复给药的安全性，包括滤泡性淋巴瘤、弥漫性大细胞淋巴瘤、套细胞淋巴瘤和小淋巴细胞淋巴瘤/慢性淋巴细胞白血病（SLL/CLL）。 （二） 确定重复结内注射Ad-ISF 35治疗的患者的药效学（PD）参数。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objectives Determine and monitor the biological responses in patients with Non-Hodgkin lymphoma (NHL) restricted to follicular lymphoma, diffuse large cell lymphoma, mantle cell lymphoma and small lymphocytic lymphoma/Chronic lymphocytic leukemia (SLL/CLL) treated with repeat intranodal injections of Ad-ISF35. Secondary Objectives 1) Determine the safety of repeat administration of Adenovirus-CD154 (Ad-ISF35) injected directly into lymph nodes of patients with Non-Hodgkin lymphoma (NHL) including follicular lymphoma, diffuse large cell lymphoma, mantle cell lymphoma and small lymphocytic lymphoma/Chronic lymphocytic leukemia (SLL/CLL). 2) Determine pharmacodynamic (PD) parameters in patients treated with repeat intranodal injections of Ad-ISF35.